uniQure (NASDAQ:QURE) Sets New 12-Month High - Time to Buy?

Key Points

• uniQure's stock reached a new 52-week high of $61.80 during trading, suggesting strong market interest with a significant increase in trading volume of 1.94 million shares.
• A number of analysts have significantly raised their price targets for uniQure, with estimates ranging from $56.00 to $95.00, indicating a general consensus rating of "Moderate Buy" with a target price of $71.75.
• Insider selling activity was noted, as CFO Christian Klemt sold 15,000 shares and CEO Matthew C. Kapusta sold 226,316 shares, reflecting notable decreases in their ownership stakes in the company.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $61.80 and last traded at $61.01, with a volume of 1941731 shares trading hands. The stock had previously closed at $57.92.

Analyst Ratings Changes

QURE has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their price objective on shares of uniQure from $13.00 to $56.00 and gave the company a "neutral" rating in a report on Thursday, September 25th. Royal Bank Of Canada reiterated an "outperform" rating on shares of uniQure in a report on Wednesday, September 24th. Cantor Fitzgerald lifted their price objective on shares of uniQure from $47.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday, September 25th. UBS Group set a $95.00 price objective on shares of uniQure in a report on Thursday, September 25th. Finally, Leerink Partners lifted their price objective on shares of uniQure from $48.00 to $68.00 and gave the company an "outperform" rating in a report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $71.75.

uniQure Stock Performance

The business's 50-day moving average price is $23.23 and its 200-day moving average price is $16.96. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock has a market cap of $3.29 billion, a PE ratio of -15.52 and a beta of 0.56.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. As a group, equities research analysts expect that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total value of $825,000.00. Following the completion of the sale, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This trade represents a 6.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the sale, the chief executive officer owned 651,454 shares of the company's stock, valued at $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 244,316 shares of company stock valued at $10,328,181 over the last quarter. 4.79% of the stock is owned by company insiders.

Institutional Trading of uniQure

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jefferies Financial Group Inc. acquired a new position in shares of uniQure in the 2nd quarter valued at $29,217,000. Vestal Point Capital LP lifted its stake in shares of uniQure by 58.4% in the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after purchasing an additional 1,767,572 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of uniQure by 471.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock valued at $25,199,000 after purchasing an additional 1,491,486 shares during the period. Sofinnova Investments Inc. lifted its stake in shares of uniQure by 185.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock valued at $21,723,000 after purchasing an additional 1,012,585 shares during the period. Finally, Aberdeen Group plc increased its holdings in uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock worth $23,485,000 after acquiring an additional 706,216 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.